Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome

Zwi N Berneman^{1

2

3}, Maxime De Laere^{4

5

6}, Paul Germonpré⁷, Manon T Huizing^{8

9

10}, Yannick Willemen^{11

12

8

13}, Eva Lion^{11

12}, Hans De Reu^{11

12}, Jolien Van den Bossche^{11

12}, Jan Van den Brande^{8

13}, Pol Specenier^{8

13}, Sevilay Altintas^{8

13}, Peter A van Dam^{13

14}, Nathalie Cools^{11

12}, Griet Nijs^{11

12

9

15}, Barbara Stein^{11

12

9}, Kim Caluwaerts^{11

16

12

9}, Annemiek Snoeckx^{17

18}, Bart Op de Beeck¹⁷, Kirsten Saevels¹⁶, Lynn Rutsaert¹⁶, Irma Vandenbosch^{11

16}, Gizem Oner^{13

14}, Martin Lammens^{13

19}, Pierre Van Damme²⁰, Sian Llewellyn-Lacey²¹, David A Price^{21

22}, Yoshihiro Oka²³, Yusuke Oji²⁴, Haruo Sugiyama²⁵, Marie M Couttenye^{26

27}, Ann L Van de Velde^{11

16

12}, Viggo F Van Tendeloo^{11

12}, Marc Peeters^{8

13}, Sébastien Anguille^{11

16

12}, Evelien L J M Smits^{11

13}

Affiliations

¹ Center for Cell Therapy & Regenerative Medicine (CCRG), Antwerp University Hospital (UZA), Edegem, Belgium. zwi.berneman@uza.be.
² Division of Hematology & Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium. zwi.berneman@uza.be.
³ Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. zwi.berneman@uza.be.
⁴ Center for Cell Therapy & Regenerative Medicine (CCRG), Antwerp University Hospital (UZA), Edegem, Belgium. maxime.delaere@uza.be.
⁵ Division of Hematology & Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium. maxime.delaere@uza.be.
⁶ Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. maxime.delaere@uza.be.
⁷ Department of Pneumology, Maria Middelares General Hospital, Ghent, Belgium.
⁸ Division of Oncology & Multidisciplinary Oncological Center Antwerp, Antwerp University Hospital, Edegem, Belgium.
⁹ Bio and Tissue Bank, Antwerp University Hospital, Edegem, Belgium.
¹⁰ Department of Antwerp Surgical Training, Anatomy and Research Centre (ASTARC), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
¹¹ Center for Cell Therapy & Regenerative Medicine (CCRG), Antwerp University Hospital (UZA), Edegem, Belgium.
¹² Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
¹³ Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Department of Molecular Imaging, Pathology, Radiotherapy and Oncology (MIPRO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
¹⁴ Division of Gynecological Oncology & Multidisciplinary Oncological Center Antwerp, Antwerp University Hospital, Edegem, Belgium.
¹⁵ Clinical Research Center (CRC) Antwerp, Antwerp University Hospital, Edegem, Belgium.
¹⁶ Division of Hematology & Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.
¹⁷ Division of Radiology, Antwerp University Hospital, Edegem, Belgium.
¹⁸ Department of Molecular Morphology and Microscopy (mVISION), Faculty of Medicine and Medical Sciences, University of Antwerp, Antwerp, Belgium.
¹⁹ Division of Anatomopathology, Antwerp University Hospital, Edegem, Belgium.
²⁰ Centre for the Evaluation of Vaccination (CEV), Vaccine and Infectious Disease Institute, Faculty of Medicine and Medical Sciences, University of Antwerp, Antwerp, Belgium.
²¹ Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
²² Systems Immunity Research Institute, Cardiff University School of Medicine, Cardiff, UK.
²³ Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
²⁴ Department of Clinical Laboratory and Biomedical Sciences, Integrated Health Design Initiative (IHDi), Osaka University Graduate School of Medicine, Osaka, Japan.
²⁵ Department of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
²⁶ Division of Nephrology, Antwerp University Hospital, Edegem, Belgium.
²⁷ Department of Translational Research in Immunology and Inflammation (TWI2N), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.

PMID: 40108626
PMCID: PMC11924853
DOI: 10.1186/s13045-025-01683-5

Published Erratum

Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome

Zwi N Berneman et al. J Hematol Oncol. 2025.

. 2025 Mar 19;18(1):34.

doi: 10.1186/s13045-025-01683-5.

Authors

Affiliations

¹ Center for Cell Therapy & Regenerative Medicine (CCRG), Antwerp University Hospital (UZA), Edegem, Belgium. zwi.berneman@uza.be.
² Division of Hematology & Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium. zwi.berneman@uza.be.
³ Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. zwi.berneman@uza.be.
⁴ Center for Cell Therapy & Regenerative Medicine (CCRG), Antwerp University Hospital (UZA), Edegem, Belgium. maxime.delaere@uza.be.
⁵ Division of Hematology & Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium. maxime.delaere@uza.be.
⁶ Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. maxime.delaere@uza.be.
⁷ Department of Pneumology, Maria Middelares General Hospital, Ghent, Belgium.
⁸ Division of Oncology & Multidisciplinary Oncological Center Antwerp, Antwerp University Hospital, Edegem, Belgium.
⁹ Bio and Tissue Bank, Antwerp University Hospital, Edegem, Belgium.
¹⁰ Department of Antwerp Surgical Training, Anatomy and Research Centre (ASTARC), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
¹¹ Center for Cell Therapy & Regenerative Medicine (CCRG), Antwerp University Hospital (UZA), Edegem, Belgium.
¹² Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
¹³ Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Department of Molecular Imaging, Pathology, Radiotherapy and Oncology (MIPRO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
¹⁴ Division of Gynecological Oncology & Multidisciplinary Oncological Center Antwerp, Antwerp University Hospital, Edegem, Belgium.
¹⁵ Clinical Research Center (CRC) Antwerp, Antwerp University Hospital, Edegem, Belgium.
¹⁶ Division of Hematology & Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.
¹⁷ Division of Radiology, Antwerp University Hospital, Edegem, Belgium.
¹⁸ Department of Molecular Morphology and Microscopy (mVISION), Faculty of Medicine and Medical Sciences, University of Antwerp, Antwerp, Belgium.
¹⁹ Division of Anatomopathology, Antwerp University Hospital, Edegem, Belgium.
²⁰ Centre for the Evaluation of Vaccination (CEV), Vaccine and Infectious Disease Institute, Faculty of Medicine and Medical Sciences, University of Antwerp, Antwerp, Belgium.
²¹ Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
²² Systems Immunity Research Institute, Cardiff University School of Medicine, Cardiff, UK.
²³ Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
²⁴ Department of Clinical Laboratory and Biomedical Sciences, Integrated Health Design Initiative (IHDi), Osaka University Graduate School of Medicine, Osaka, Japan.
²⁵ Department of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
²⁶ Division of Nephrology, Antwerp University Hospital, Edegem, Belgium.
²⁷ Department of Translational Research in Immunology and Inflammation (TWI2N), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.

PMID: 40108626
PMCID: PMC11924853
DOI: 10.1186/s13045-025-01683-5

No abstract available

PubMed Disclaimer

Erratum for

WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.
Berneman ZN, De Laere M, Germonpré P, Huizing MT, Willemen Y, Lion E, De Reu H, Van den Bossche J, Van den Brande J, Specenier P, Altintas S, van Dam PA, Cools N, Nijs G, Stein B, Caluwaerts K, Snoeckx A, Op de Beeck B, Saevels K, Rutsaert L, Vandenbosch I, Oner G, Lammens M, Van Damme P, Llewellyn-Lacey S, Price DA, Oka Y, Oji Y, Sugiyama H, Couttenye MM, Van de Velde AL, Van Tendeloo VF, Peeters M, Anguille S, Smits ELJM. Berneman ZN, et al. J Hematol Oncol. 2025 Jan 23;18(1):9. doi: 10.1186/s13045-025-01661-x. J Hematol Oncol. 2025. PMID: 39849594 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- BioMed Central
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome

Affiliations

Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources